Abstract
Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Current Pharmaceutical Biotechnology
Title: Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Volume: 1 Issue: 1
Author(s): Ignacio Perez-Roger, Carmen Ivorra, Antonio Diez, Maria Jose Cortes, Enric Poch, Silvia M. Sanz-Gonzalez and Vicente Andres
Affiliation:
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Abstract: Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Export Options
About this article
Cite this article as:
Perez-Roger Ignacio, Ivorra Carmen, Diez Antonio, Cortes Jose Maria, Poch Enric, Sanz-Gonzalez M. Silvia and Andres Vicente, Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases, Current Pharmaceutical Biotechnology 2000; 1 (1) . https://dx.doi.org/10.2174/1389201010001010107
DOI https://dx.doi.org/10.2174/1389201010001010107 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs
Anti-Cancer Agents in Medicinal Chemistry Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Biologically Active Insulin-derived Peptides
Protein & Peptide Letters Heat Shock Proteins: A Potential Anticancer Target
Current Drug Targets Amaranth: A Pseudo-Cereal with Nutraceutical Properties
Current Nutrition & Food Science Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
Current Molecular Medicine Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Viral Origins of Human Cancer
Current Medicinal Chemistry Cell Penetrating Peptides for In Vivo Molecular Imaging Applications
Current Pharmaceutical Design Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer
Current Pharmaceutical Design Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics PI3K-Akt Signaling and Viral Infection
Recent Patents on Biotechnology Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy
Current Medicinal Chemistry Adenovirus-Based Cancer Gene Therapy
Current Gene Therapy Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia
Current Cancer Drug Targets Apoptosis: Its Functions and Control in the Ocular Lens
Current Molecular Medicine Interactions Between Cholinergic and Fibroblast Growth Factor Receptors in Brain Trophism and Plasticity
Current Protein & Peptide Science